NCT03557788View on ClinicalTrials.gov

Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 7, 2018

Primary Completion Date

August 13, 2021

Study Completion Date

August 13, 2021

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Rifaximin Oral Tablet

PO 550mg TDS for 2 weeks

Trial Locations (1)

Unknown

Soh Yu Sen, Alex, Singapore

All Listed Sponsors
collaborator

National University of Singapore

OTHER

lead

National University Hospital, Singapore

OTHER

NCT03557788 - Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter